Critical Survey: PROCEPT BioRobotics (PRCT) versus Its Peers
by Mitch Edgeman · The Markets DailyPROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its rivals? We will compare PROCEPT BioRobotics to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, profitability, risk and dividends.
Profitability
This table compares PROCEPT BioRobotics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PROCEPT BioRobotics | -32.53% | -30.62% | -22.10% |
| PROCEPT BioRobotics Competitors | -278.23% | -150.07% | -21.87% |
Insider & Institutional Ownership
89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 4.0% of PROCEPT BioRobotics shares are owned by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
PROCEPT BioRobotics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics’ rivals have a beta of 2.50, suggesting that their average share price is 150% more volatile than the S&P 500.
Earnings and Valuation
This table compares PROCEPT BioRobotics and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| PROCEPT BioRobotics | $337.34 million | -$95.57 million | -9.90 |
| PROCEPT BioRobotics Competitors | $1.89 billion | $137.23 million | 10.69 |
PROCEPT BioRobotics’ rivals have higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for PROCEPT BioRobotics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PROCEPT BioRobotics | 2 | 9 | 2 | 3 | 2.38 |
| PROCEPT BioRobotics Competitors | 4251 | 10479 | 18202 | 824 | 2.46 |
PROCEPT BioRobotics currently has a consensus price target of $25.50, indicating a potential upside of 32.81%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 25.59%. Given PROCEPT BioRobotics’ higher probable upside, equities research analysts plainly believe PROCEPT BioRobotics is more favorable than its rivals.
Summary
PROCEPT BioRobotics rivals beat PROCEPT BioRobotics on 8 of the 13 factors compared.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.